These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 37088950)

  • 1. Advances in research on immune escape mechanism of glioma.
    Guo X; Wang G
    CNS Neurosci Ther; 2023 Jul; 29(7):1709-1720. PubMed ID: 37088950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma.
    Yan D; Li W; Liu Q; Yang K
    Front Immunol; 2022; 13():914618. PubMed ID: 35769466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results.
    Picca A; Finocchiaro G
    Curr Opin Oncol; 2022 Nov; 34(6):653-660. PubMed ID: 36000367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel chemokine-based signature for prediction of prognosis and therapeutic response in glioma.
    Fan W; Wang D; Li G; Xu J; Ren C; Sun Z; Wang Z; Ma W; Zhao Z; Bao Z; Jiang T; Zhang Y
    CNS Neurosci Ther; 2022 Dec; 28(12):2090-2103. PubMed ID: 35985661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Challenges and Future of Immunotherapy for Gliomas.
    Wu A; Lim M
    Cancer J; 2021 Sep-Oct 01; 27(5):371-378. PubMed ID: 34570451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.
    Richardson LG; Miller JJ; Kitagawa Y; Wakimoto H; Choi BD; Curry WT
    Neurosurg Focus; 2022 Feb; 52(2):E6. PubMed ID: 35104795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pivotal Role of STAT3 in Shaping Glioblastoma Immune Microenvironment.
    Piperi C; Papavassiliou KA; Papavassiliou AG
    Cells; 2019 Nov; 8(11):. PubMed ID: 31698775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of TAMs marker genes in glioma for predicting prognosis and immunotherapy response.
    Zhao Z; Wang Z; Wu Y; Liao D; Zhao B
    Mol Immunol; 2022 Apr; 144():78-95. PubMed ID: 35203024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.
    Friedrich M; Bunse L; Wick W; Platten M
    Curr Opin Oncol; 2018 Nov; 30(6):368-374. PubMed ID: 30102604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive characterization of TNFSF14/LIGHT with implications in prognosis and immunotherapy of human gliomas.
    Han M; Sun Y; Zhao W; Xiang G; Wang X; Jiang Z; Xue Z; Zhou W
    Front Immunol; 2022; 13():1025286. PubMed ID: 36341396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities.
    Linares CA; Varghese A; Ghose A; Shinde SD; Adeleke S; Sanchez E; Sheriff M; Chargari C; Rassy E; Boussios S
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging immune-based technologies for high-grade gliomas.
    Giotta Lucifero A; Luzzi S
    Expert Rev Anticancer Ther; 2022 Sep; 22(9):957-980. PubMed ID: 35924820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional characterization of TSPAN7 as a novel indicator for immunotherapy in glioma.
    Chen L; Liu H; Li Y; Lin X; Xia S; Wanggou S; Li X
    Front Immunol; 2023; 14():1105489. PubMed ID: 36845098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of cancer immunotherapy through pyroptosis: A pyroptosis-related signature predicts survival benefit and potential synergy for immunotherapy in glioma.
    Zeng Y; Cai Y; Chai P; Mao Y; Chen Y; Wang L; Zeng K; Zhan Z; Xie Y; Li C; Zhan H; Zhao L; Chen X; Zhu X; Liu Y; Chen M; Song Y; Zhou A
    Front Immunol; 2022; 13():961933. PubMed ID: 35990696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The unique immune ecosystems in pediatric brain tumors: integrating single-cell and bulk RNA-sequencing.
    Cao L; Xie W; Ma W; Zhao H; Wang J; Liang Z; Tian S; Wang B; Ma J
    Front Immunol; 2023; 14():1238684. PubMed ID: 38094301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment.
    Zhang N; Zhang H; Wang Z; Dai Z; Zhang X; Cheng Q; Liu Z
    Front Immunol; 2021; 12():691811. PubMed ID: 34489938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
    Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
    Front Immunol; 2021; 12():557994. PubMed ID: 34220791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy.
    Najem H; Khasraw M; Heimberger AB
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.